New trends in CLL treatment.
We review here results obtained from the various treatment modalities that have been used in CLL patients: chemotherapy; radiotherapy; splenectomy; leukapheresis; monoclonal antibodies and other immunomodulating agents. We conclude that it is still unclear whether patients in stage A (good prognosis) should be treated; intermediate forms of the disease (stage B) should, in most cases, be treated, but a better treatment than chlorambucil has not emerged; results from the Cooperative Group on CLL of Société Française d'Hématologie indicate that significant progress in the therapy of the advanced stage (stage C) has been achieved with the introduction of the CHOP regimen, using low doses of adriamycin; radiotherapy, splenectomy and immunomodulators such as levamizol, interleukins or interferons, and possibly monoclonal antibodies, are now being actively tested; the results are not yet conclusive.
Travade
P
P
Chastang
C
C
Dighiero
G
G
Binet
J L
JL
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007937:Leukapheresis; D007945:Leukemia, Lymphoid / Q000401:mortality / Q000628:therapy*; D008198:Lymph Nodes / Q000528:radiation effects; D013154:Spleen / Q000528:radiation effects; D013156:Splenectomy; D014916:Whole-Body Irradiation
D000911:Antibodies, Monoclonal